Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 8M | 12M | 5M | 0 | 0 |
| Gross Profit | 4M | 4M | 1M | -30K | -26K |
| Operating Income | -10M | -9M | -14M | -4M | -1M |
| EBITDA | -9M | -10M | -25M | -8M | -1M |
| Net Income | -25M | -43M | -30M | -10M | -458K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Todos Medical Ltd. (TOMDF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -37.1%, EPS growth of +72.5%, a dividend yield of 0.0%. What stands out right now is revenue -37.1%, EPS +72.5%, free cash flow +77.4% with operating margin -126.7% and ROIC -243.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TOMDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TOMDF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TOMDF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TOMDF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$457.5K
+95.3% YoY
Free Cash Flow
-$1.1M
+16.1% YoY
Revenue Growth
-37.1%
EPS Growth
+72.5%
Gross Margin
56.0%
Net Margin
-324.8%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 8M | 12M | 5M | 0 | 0 |
| Gross Profit | 4M | 4M | 1M | -30K | -26K |
| Operating Income | -10M | -9M | -14M | -4M | -1M |
| EBITDA | -9M | -10M | -25M | -8M | -1M |
| Net Income | -25M | -43M | -30M | -10M | -458K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 34K | 189K | 935K | 12K | 64K |
| Total Assets | 15M | 15M | 6M | 91K | 199K |
| Total Liabilities | 50M | 39M | 17M | 6M | 1M |
| Shareholder Equity | -36M | -24M | -11M | -6M | -1M |
| Total Debt | 38M | 32M | 11M | 4M | 630K |
| Net Debt | 38M | 32M | 11M | 4M | 566K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+17.2% YoY
Capital Expenditures
15K
-1332.4% YoY
Free Cash Flow
1M
+16.1% YoY
Key ratios
Gross Margin
56.0%
Operating Margin
-126.7%
Net Margin
-324.8%
ROE
83.7%
Debt / Equity
-1.08x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.